Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.

Authors

Heinz-Josef LenzFollow
Sara LonardiFollow
Vittorina ZagonelFollow
Eric Van CutsemFollow
M Luisa LimonFollow
Ka Yeung Mark WongFollow
Alain HendliszFollow
Massimo AgliettaFollow
Pilar Garcia-AlfonsoFollow
Bart NeynsFollow
Andrea Spallanzani
Dana Backlund CardinFollow
Tomislav DragovitchFollow
Usman Shah MDFollow
Ajlan Atasoy
Jean-Marie LedeineFollow
Michael J. OvermanFollow

Publication/Presentation Date

1-2020

Published In/Presented At

Lenz, H., Lonardi, S., Zagonel, V., Van Cutsem, E., Limon, L., Wong, K., Hendlisz, A., Aglietta, M., Garcia-Alfonso, P., Neyns, B., Spallazani, A., Backlund Cardin, D., Dragovich, T., Shah, U., Atasoy, A., Ledeine, J., & Overman, M. (2020, January). Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. Presentation presented at: ASCO Gastrointestinal Cancers Symposium, San Francisco, CA.

Disciplines

Medicine and Health Sciences | Oncology

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty

Document Type

Presentation